WO2004005506A2 - Zellaufschluss von bakterien mit der domäne 3 von ef-tu - Google Patents
Zellaufschluss von bakterien mit der domäne 3 von ef-tu Download PDFInfo
- Publication number
- WO2004005506A2 WO2004005506A2 PCT/EP2003/007068 EP0307068W WO2004005506A2 WO 2004005506 A2 WO2004005506 A2 WO 2004005506A2 EP 0307068 W EP0307068 W EP 0307068W WO 2004005506 A2 WO2004005506 A2 WO 2004005506A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- domain
- amino acids
- cells
- substances
- cytoskeleton
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
Definitions
- the invention relates to the use of substances that bind to the bacterial elongation factor EF-Tu for cell disruption or for the lysis of cells.
- the invention further relates to a cell disruption system or a cell disruption method.
- Cells in particular bacterial cells, are frequently used to produce compounds using molecular genetic techniques, for example by homologous or heterologous gene expression and expression of synthetically active enzymes.
- Peptide compounds, triglycerides, wax esters and PHAs are preferably produced, and in particular those compounds which can be used in biotechnology, medicine, in the pharmaceutical sector or in other fields.
- heterologous gene expression the compounds formed are non-natural components of the cells or bacteria used.
- the production of a wide variety of compounds by means of gene expression has been extensively described in the prior art (see, for example, Q. Bi et al., Applied Biochemistry & Biotechnology, 95 (1) (2001) 23-30; D.
- the production of the compounds produced in the cells generally requires that the cells or bacteria have to be lysed.
- a Such lysis is always mandatory if the desired compounds cannot be removed from the living cell. In this case, the desired compounds can only be released by lysis and sent for further processing (down-stream processing).
- enzymes such as lysozyme
- lysozyme can be added which lyse the cell envelope, whereby lysis could not be achieved by induced lysozyme expression.
- the cell envelope is destroyed, the cell can be regarded as "unlocked" (TR Hopkins, Bioprocess Technology (New York) 12 (1991), 57-83; JA Asenjo et al., Bioprocess Technology (New York) 9 (1990) 143- 75).
- Methods can also be used for lysis in which mechanical shear forces come into effect to destroy the cells. An example of such a method is the use of a French press.
- the object of the present invention was therefore to provide an improved method for cell disruption, in particular a method which can be used advantageously in biotechnological production processes.
- the bacterial protein EF-Tu contains domains 1, 2 and 3 (H. Song et al., J. Mol. Biol. 285 (1 999) 1 245-1 256).
- the sequences of the EF-Tu protein and its coding gene have been published for Escherichia coli and a number of other Eu bacteria and are accessible in databases.
- EF-Tu is a protein that contains three domains.
- domain 1 includes amino acids 8 to 204, amino acids 172 to 204 forming a connection structure to domain 2.
- Domain 2 includes amino acids 205 to 298 and domain 3 includes amino acids 299 to 394.
- EF-Tu is a 3-domain protein, as shown in Figure 1.
- the protofilaments of the cytoskeleton arise in the living cell in that domains 2 and 3 of EF-Tu proteins (monomer or integrated in a protofilament and only transiently free) with domains 3 and 2 neighboring EF-Tu proteins interact.
- domains 2 and 3 of EF-Tu proteins monomer or integrated in a protofilament and only transiently free
- domains 3 and 2 neighboring EF-Tu proteins interact.
- chains so-called protofilaments, are formed in this way, which combine to form a network (see figure 2).
- Other factors may be associated with this network, such as FtsZ, MreB and / or M6I.
- Stability and / or expression of such protofilaments and networks in bacterial cells can be prevented according to the invention, the death of the bacterial cell occurring as a result of lysis.
- a particularly advantageous procedure of the invention is as follows.
- the DNA section of the EF-Tu gene from Escherichia coli, which codes for domain 3, is obtained and transferred and expressed in E. coli cells by means of molecular genetic techniques.
- the cells still have the native EF-Tu gene and can express it.
- the additionally synthesized domain 3 polypeptides compete with the native EF-Tu proteins for the binding sites for the formation of the protofilaments.
- a domain 3 polypeptide is incorporated as a chain link instead of a native EF-Tu protein, this leads to chain termination due to the lack of the second binding site (domain 2 is essential for chain formation) on the domain 3 polypeptide.
- the protofilament stops growing, the cytoskeletal network is weakened and eventually collapses.
- the cell's cytoplasmic membrane loses its suspension.
- the cytoplasmic membrane is suspended from the cytoskeleton. This destroys the cell wall, which is positioned and supported in the living bacterial cell by the cytoplasmic membrane (see FIG. 5). Loss of cell wall and cytoplasmic membrane means an exposure of the cell contents so that the cell is lysed (see FIGS. 5 and 6). The cell content can thus be obtained without further cell disruption.
- Cells which are used for biotechnological production processes, such as heterologous expression, production of proteins, in particular for biotechnological or medical purposes, can thus be disrupted by introducing a sequence into them prior to their use in production which Species corresponding domain of the EF-Tu coded.
- the substances used for cell disruption contain fractions which bind to EF-Tu in the region of amino acids 218 to 224 of domain 2 and / or in the region of amino acids 317 to 328 or / and 343 to 354 of domain 3.
- Different secondary structures occur within domains 2 and 3.
- intracellularly expressed peptide substances are used which are based on oligopeptides which bind to EF-Tu, preferably in the region of the matching sites of domains 2 or / and 3.
- oligopeptides can contain sections of the amino acid sequences of domains 2 or / and 3 with a length of preferably 4 to preferably 20 amino acids, particularly preferably 5 to 15 amino acids and particularly preferably with a length of 6 to 12 amino acids.
- the substances contain partial sections or the total range of the amino acid sequences from domain 3 with a length of at least 4 and in particular at least 5 amino acids and which at the same time does not correspond to any section of the amino acid sequences from domain 2.
- intracellularly expressed peptidic compounds In addition to intracellularly expressed peptidic compounds, intracellularly expressed peptidomimetics can also be used advantageously.
- Another object of the invention is a method for disrupting cells, in which components of the cytoskeleton are destabilized in the cells.
- Cytoskeletal elements that can be altered to weaken the cytoskeleton include, for example, FtsZ, MReB, Mbl, and contractile proteins, and particularly EF-Tu.
- substances which bind to constituents of the cytoskeleton, in particular to EF-Tu, and which have been explained above, are particularly preferably used.
- a construct is introduced into the cells which, in addition to the gene for the destabilizing substance, contains further coding sequences which make it possible to induce the start of the synthesis of the substance, for example the domain 3 polypeptide, from the outside. In this way it is possible to precisely control the time of cell lysis in the cell culture from the outside.
- Induction by a quorum-coupled or / and cell culture-self-sufficient process is another suitable form for initiating cell lysis.
- the invention further comprises a construct comprising a sequence which codes for a constituent of the substance destabilizing the cytoskeleton of cells.
- This construct preferably further comprises at least one gene segment which allows the induction of the synthesis of the substance destabilizing the cytoskeleton.
- FIG. 7 Advantageous designs of the construct are shown in FIG. 7. As soon as the induction has taken place, the lysis of the cells is brought about within a cell generation by the interaction of EF-Tu, domain 3 polypeptide, cytoplasmic membrane and cell wall.
- Fig. 1 a EF-Tu (GDP form from E. coli; result of an X-ray structure analysis; figure taken from the literature and modified).
- the 3 domains of the protein molecule are marked.
- a 'and b denote connection sequences b) Like a), but different form of representation.
- the numbers mark the positions of the amino acid residues; N-terminus and C-terminus are given.
- Gold markers used for marking purposes.
- EF-Tu-GFP-His fusion clones are to be generated.
- the ideal fusion point for EF-Tu is the C-terminus, which protrudes between domains 2 and 3 (Song et al., 1 999).
- the same fusion point can also be chosen for a domain-3 fusion construct.
- the domain 3 fusion construct can be used for in vivo competition experiments. It seems sensible to introduce a C-terminal cysteine (the only one in domain 3) for chemical labeling alternatives.
- the starting point is genomic DNA from an E. coli K-12 strain. in the
- Tu was expressed in addition to the cell's own EF-Tu;
- Lad Repressor p u ac o- ⁇ modified Lac promoter (according to LUTZ and BUJARD, 1 997)
- the promoters ara, T7 or bdA (quorum sensing) can also be used as alternatives to the specified promoter.
- Clones are plated on selection agar (here: LB / ampicillin) and grown overnight at 37 ° C
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003249934A AU2003249934A1 (en) | 2002-07-02 | 2003-07-02 | Bacterial cell digestion by means of domain 3 of ef-tu |
US10/520,145 US20060172407A1 (en) | 2002-07-02 | 2003-07-02 | Bacterial cell digestion |
EP03762592A EP1517986A2 (de) | 2002-07-02 | 2003-07-02 | Zellaufschluss von bakterien mit der domäne 3 von ef-tu |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10229645.6 | 2002-07-02 | ||
DE10229645A DE10229645A1 (de) | 2002-07-02 | 2002-07-02 | Zellaufschluss von Bakterien |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004005506A2 true WO2004005506A2 (de) | 2004-01-15 |
WO2004005506A3 WO2004005506A3 (de) | 2004-05-06 |
Family
ID=30009775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/007068 WO2004005506A2 (de) | 2002-07-02 | 2003-07-02 | Zellaufschluss von bakterien mit der domäne 3 von ef-tu |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060172407A1 (de) |
EP (1) | EP1517986A2 (de) |
AU (1) | AU2003249934A1 (de) |
DE (1) | DE10229645A1 (de) |
WO (1) | WO2004005506A2 (de) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19929485A1 (de) * | 1999-06-28 | 2001-01-11 | Fraunhofer Ges Forschung | Lytisches Enzym |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE200300530A (et) * | 2001-04-30 | 2004-04-15 | Novologix Gmbh | EF-Tu proteiiniga seostuvate ainete kasutamine antibakteriaalse vahendi valmistamiseks, sel viisil saadud antibakteerikum ning meetod uute bakterivastaste toimeainete identifitseerimiseks |
-
2002
- 2002-07-02 DE DE10229645A patent/DE10229645A1/de not_active Withdrawn
-
2003
- 2003-07-02 EP EP03762592A patent/EP1517986A2/de not_active Withdrawn
- 2003-07-02 WO PCT/EP2003/007068 patent/WO2004005506A2/de not_active Application Discontinuation
- 2003-07-02 US US10/520,145 patent/US20060172407A1/en not_active Abandoned
- 2003-07-02 AU AU2003249934A patent/AU2003249934A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19929485A1 (de) * | 1999-06-28 | 2001-01-11 | Fraunhofer Ges Forschung | Lytisches Enzym |
Non-Patent Citations (3)
Title |
---|
HEFFRON S E ET AL: "Structure of an EF-Tu complex with a thiazolyl peptide antibiotic determined at 2.35 A resolution: atomic basis for GE2270A inhibition of EF-Tu." BIOCHEMISTRY. UNITED STATES 11 JAN 2000, Bd. 39, Nr. 1, 11. Januar 2000 (2000-01-11), Seiten 37-45, XP001172470 ISSN: 0006-2960 * |
HOGG T ET AL: "Inhibitory mechanisms of antibiotics targeting elongation factor Tu." CURRENT PROTEIN & PEPTIDE SCIENCE. NETHERLANDS FEB 2002, Bd. 3, Nr. 1, Februar 2002 (2002-02), Seiten 121-131, XP002270310 ISSN: 1389-2037 * |
SONG H ET AL: "Crystal structure of intact elongation factor EF-Tu from Escherichia coli in GDP conformation at 2.05 A resolution" JOURNAL OF MOLECULAR BIOLOGY 22 JAN 1999 UNITED KINGDOM, Bd. 285, Nr. 3, 22. Januar 1999 (1999-01-22), Seiten 1245-1256, XP002270308 ISSN: 0022-2836 in der Anmeldung erwähnt * |
Also Published As
Publication number | Publication date |
---|---|
EP1517986A2 (de) | 2005-03-30 |
WO2004005506A3 (de) | 2004-05-06 |
US20060172407A1 (en) | 2006-08-03 |
DE10229645A1 (de) | 2004-05-19 |
AU2003249934A1 (en) | 2004-01-23 |
AU2003249934A8 (en) | 2004-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69434520T3 (de) | Biotinylierung von proteinen | |
DE69930164T2 (de) | Intein-vermittelte cyclisierung von peptiden | |
DE69936103T2 (de) | Fusionsproteine bestehend aus proteingerüst und bibliotheken von zufälligen peptiden | |
DE3546806C2 (de) | ||
DE3752363T2 (de) | Herstellung synthetischer dns und deren verwendung bei der synthese grosser polypeptide | |
DE69629576T2 (de) | Verfahren zur herstellung von rekombinanten plasmiden | |
DE60208343T2 (de) | FUSIONSPROTEINE aus hirudin und proinsulin oder insulin | |
DE69636536T2 (de) | Sekretionssignal-Gen und dieses enthaltender Expressionsvektor | |
DE212012000234U1 (de) | Modifzierte Cascade-Ribonukleoproteine und Anwendungen davon | |
DE60023860T2 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
SK116896A3 (en) | Enhanced secretion of polypeptides | |
FI87800C (fi) | Foerfarande foer framstaellning av glukagon i jaest | |
DE69534941T2 (de) | Herstellung einer multikombinatorischen bank von antikörpergene-exprimierende vektoren | |
EP0875567B1 (de) | Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung | |
DE102020205703A1 (de) | Expression von Kollagenpeptid-Komponenten in prokaryotischen Systemen | |
DE60209883T2 (de) | Übersekretierte peptide, deren herstellung, und gleichzeitige verbesserung der sekretierten form eines oder mehrerer anderer polypeptide | |
EP1025253B1 (de) | Positiv-negativ-selektion bei der homologen rekombination | |
DE10196565B4 (de) | Rekombinantes Human-Parathyroidhormon erzeugender Hefe-Transformant und Verfahren zur Herstellung des Hormons | |
DE69931382T2 (de) | Intein vermittelte peptidligation | |
DE69930938T2 (de) | Verfahren zur herstellung eines peptids mit einem pi grösser als 8 oder kleiner als 5 | |
EP2330186B1 (de) | Verfahren zur synthetisierung eines proteins mit hohem anteil einer spezifischen aminosäure durch simultane expression mit der trna der spezifischen aminosäure | |
DE69629808T2 (de) | Promotoren für Gen Expression | |
DE69732583T2 (de) | Verfahren zur Spaltung eines chimeren Proteins mittels eines 'processing'-Enzyms | |
WO1993001287A1 (de) | Rekombinante antikörper an der oberfläche von e.coli | |
EP1517986A2 (de) | Zellaufschluss von bakterien mit der domäne 3 von ef-tu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003762592 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003762592 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006172407 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10520145 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10520145 Country of ref document: US |